Navigation Links
Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
Date:10/26/2008

o-treat pathogens. Introduced more than 50 years ago, tetracyclines remain among the most commonly used antiinfective agents to combat bacterial infections. However, the emergence of resistance has curtailed their effectiveness in certain infections. Paratek has utilized its expertise to create AMC compounds, such as PTK 0796, that retain the appealing safety and spectrum of activity of the tetracyclines while overcoming tetracycline and multi-drug resistance.

Representing one of the top therapeutic categories, the antibiotics market generates worldwide sales of over $26 billion, despite the availability of low-priced generic products for many infections. In recent years, eight antibiotics have attained annual sales of more than $1 billion each. The growing medical problem of drug-resistant bacteria presents a new and expanding market opportunity. Bacterial resistance is causing many of the current antibiotics to lose efficacy, while the pipeline of replacement products that target antibiotic resistance is remarkably thin.

About Paratek Pharmaceuticals

Paratek Pharmaceuticals, Inc. is engaged in the discovery and commercialization of new therapeutics that treat serious and life-threatening diseases, with a particular focus on the growing worldwide problem of antibiotic resistance. Paratek is advancing novel compounds that can circumvent or block bacterial resistance. Paratek's lead compound, PTK 0796, is a broad-spectrum antibiotic derived from the tetracycline class with oral and IV formulations that is being developed for the treatment of the most common and serious hospital bacterial infections, including those caused by resistant strains such as MRSA (methicillin-resistant Staphylococcus aureus) and MDRSP (multi-drug resistant Streptococcus pneumoniae). Oral and IV formulations of PTK 0796 were compared to Zyvox (R) in a recently completed Phase 2 clinical study in complicated skin and skin structure infections (cSSSIs). In addition to PTK 0
'/>"/>

SOURCE Paratek Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Promising Data from Paratek Pharmaceuticals MAR Inhibitor Program Presented in Late Breaker Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
2. Paratek Pharmaceuticals Announces the Close of $40 Million Private Placement to Finance Programs to Combat MRSA Infections
3. Paratek to Present Clinical Data in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Spherix Reports Second Quarter Earnings
6. Tapestry Reports Second Quarter 2007 Results
7. Callisto Reports on Second-Quarter 2007 Milestones
8. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
9. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
10. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
11. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... Novel t reatments   entering the ... GBI Research . ... driven primarily by the introduction of numerous premium therapies, particularly ... or combine with generic chemotherapies. Analysis from business ... Market to 2020 - forecasts the value of the ...
(Date:6/1/2015)... , June 1, 2015 Symbiotix Biotherapies, ... $2.3 million Phase 2 Small Business Technology Transfer (STTR) ... National Institute of Allergy and Infectious Diseases (NIAID). The ... developing a novel class of molecular therapeutics from ... clinical candidate, Polysaccharide A (PSA), is the first molecule ...
(Date:6/1/2015)... June 1, 2015   OTC Markets Group ... and Connected financial marketplaces for 10,000 U.S. and ... San Diego -based biopharmaceutical company, on ... America,s only public venture market for entrepreneurial and ... http://photos.prnewswire.com/prnh/20110118/MM31963LOGO "We,re happy to ...
Breaking Medicine Technology:New Therapies to Enhance Increasingly Competitive Non-Small Cell Lung Cancer Treatment Market 2New Therapies to Enhance Increasingly Competitive Non-Small Cell Lung Cancer Treatment Market 3Symbiotix Biotherapies Announces $2.3 Million Award from NIH's National Institute of Allergy and Infectious Diseases (NIAID) 2OTC Markets Group Congratulates OncoSec Medical on NASDAQ Listing 2
... /PRNewswire-Asia/ -- Bristol-Myers Squibb Company (NYSE: ... (NYSE: SCR ), a leading pharmaceutical company ... the strategic partnership formed last year to include a ... agreed to co-develop BMS-795311, Bristol-Myers Squibb,s preclinical small molecule ...
... SAN DIEGO, Dec. 13, 2011  BioMed Realty Trust, Inc. ... has entered into a definitive agreement to acquire Prudential ... Street properties.  BioMed previously acquired a 20% interest in ... venture entered into between BioMed and PREI.  The Rogers ...
Cached Medicine Technology:Simcere and Bristol-Myers Squibb Enter Innovative Partnership to Develop Cardiovascular Compound 2Simcere and Bristol-Myers Squibb Enter Innovative Partnership to Develop Cardiovascular Compound 3Simcere and Bristol-Myers Squibb Enter Innovative Partnership to Develop Cardiovascular Compound 4Biomed Realty Trust to Acquire Remaining 80% Interest in Rogers Street Properties in Cambridge, Massachusetts for $308 Million - Increasing Ownership to 100% 2Biomed Realty Trust to Acquire Remaining 80% Interest in Rogers Street Properties in Cambridge, Massachusetts for $308 Million - Increasing Ownership to 100% 3Biomed Realty Trust to Acquire Remaining 80% Interest in Rogers Street Properties in Cambridge, Massachusetts for $308 Million - Increasing Ownership to 100% 4
(Date:6/1/2015)... Linda Kincaid, age 67, knew something was wrong. She constantly ... thought it was just a part of getting older, but ... After going to the doctor, she received a distressing diagnosis: ... might happen to her. , Linda is not alone. As ... each year. Valve disease involves damage to one or more ...
(Date:6/1/2015)... Portland, Ore. (PRWEB) June 01, 2015 ... Plans (AHIP) announced today a new, interactive Affordable ... support large employers. The course, called “Affordable Care ... care professionals with the strategic and consultative insights ... employers as they navigate the impacts of the ...
(Date:6/1/2015)... NY (PRWEB) June 01, 2015 For ... patients requesting celebrity features. Much like one would request ... stars’ noses, eyes, cheeks, chin and more to illustrate ... filtering apps like FaceTune are ushering in a new ... Manhattan facial plastic surgeon, Sam Rizk, MD, FACS notes ...
(Date:6/1/2015)... June 01, 2015 Listen to Volvo’s ... automotive companies are using more granular data to create ... comparatively new industry voices in Josep Celaya Gonzalez, CIO ... start-up ParkTAG. As an automotive insurer, MAPFRE are well ... an easy-to-use solution to the driver. Award winning start-up ...
(Date:6/1/2015)... 2015 A University of Texas ... signaling proteins that activate protein degradation, which helps ... 1 , The study published April 3rd ... Spraque-Dawley rats 2-3 months of age who performed ... given either whey protein (.4g/kg), low-dose Sustamine (.1g/kg), ...
Breaking Medicine News(10 mins):Health News:A New Online Resource for Those Living with Heart Valve Disease 2Health News:A New Online Resource for Those Living with Heart Valve Disease 3Health News:Cambia Partners with AHIP to Offer Expert Series ACA Training Course 2Health News:Cambia Partners with AHIP to Offer Expert Series ACA Training Course 3Health News:Instagram Filters Launch New Facial Plastic Surgery Trend 2Health News:Complimentary Webinar: Volvo, MAPFRE and Award Winning Start-Up discuss new Frontier of In-Car Services 2Health News:Study Shows Taking Sustamine® L-Alanyl-L-Glutamine May Reduce Muscle Protein Breakdown After Resistance Exercise 2Health News:Study Shows Taking Sustamine® L-Alanyl-L-Glutamine May Reduce Muscle Protein Breakdown After Resistance Exercise 3
... of poor children with congenital heart diseases (CHD) here moved ... the US by a non-profit organization. About 40-50 NRIs have ... keen to sponsor a child or two every year ... born in India with CHD. Only six to eight percent ...
... devised a new system that ranks foods according to ... and developed// by a panel of independent nutritionists, dietitians, ... as well as members of the government’s Scientific Advisory ... developed by the UK’s Food Standards Agency (FSA) has ...
... change in the genetic constitution is what makes each ... is unraveled, then health care can be individualized according ... same genetic code, how those genes express themselves at ... medicines and dietary advice. According to a recent study, ...
... among couples who smoke according to a new study// which ... stroke than cigarette-smoking women with non-smoking spouses. ,The study ... total stroke and ischemic stroke (a stroke caused by a ... groups of women. The relative risk of total stroke was ...
... fine combing of wet hair may be far more ... ,Researchers have used single blind randomized controlled trial ... counter insecticide treatments against head lice in United Kingdom. ... more effective than current over the counter chemical treatments ...
... with severe asthma according to a recent study.// This ... of antioxidants such as vitamin C and incidence of ... intakes and blood concentrations of antioxidants, including vitamin C, ... without asthma. , ,Men with severe asthma had ...
Cached Medicine News:Health News:Nutrient Profiling System Launched By Food Officials in UK 2Health News:Learning Just How Different We Are 2Health News:Combing Hair More Effective Than OTC Medicine For Head Lice 2
Coibri handle. Pierse tips with 6 mm platform. 2.5 mm angled tips. Manufactured in titanium....
Straight shafts with 2.0 mm, 1 x 2 Elschnig style teeth. Serrated handle with polished finish. Handle: Wide....
Straight shafts with 45 degrees, 0.12 mm, 2 x 3 teeth and tying platform. Serrated handle with polished finish....
Straight shafts with 0.1 mm Pierse tips. Flat smooth handle with dull finish....
Medicine Products: